Roxadustat

Drug Profile

Roxadustat

Alternative Names: ASP 1517; FG-4592

Latest Information Update: 22 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator FibroGen
  • Developer Astellas Pharma; AstraZeneca; FibroGen
  • Class Amides; Antianaemics; Carboxylic acids; Isoquinolines; Small molecules
  • Mechanism of Action Basic helix loop helix transcription factor modulators; Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anaemia
  • Discontinued Sickle cell anaemia

Most Recent Events

  • 07 Aug 2017 FibroGen announces intention to submit NDA to US FDA for Anaemia in 2018
  • 02 Aug 2017 Astellas Pharma completes a phase III trial for Anaemia (In chronic kidney disease patients undergoing peritoneal dialysis) in Japan (PO) (NCT02780726)
  • 05 Jun 2017 European Patent Office gave a decision against FibroGen for an opposition filed by Akebia Therapeutics, Bayer Group, and Glaxo Group for the European patent number 2 322 155, related to the therapeutic use of certain small molecule inhibitors of hypoxia-inducible factor (HIF) prolyl hydroxylase, in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top